Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)

Ronald G. Hall, Michael Thatcher, Wei Wei, Shibin Varghese, Lincy Varughese, Michelle Ndiulor, Kenna D. Payne

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a predominant pathogen resulting in significant morbidity and mortality. Optimal dosing of anti-MRSA agents is needed to help prevent the development of antimicrobial resistance and to increase the likelihood of a favorable clinical outcome. Areas covered: This review summarizes the available data for antimicrobials routinely used for MRSA infections that are not administered orally or topically. We make recommendations and highlight the current gaps in the literature. A PubMed (1966–Present) search was performed to identify relevant literature for this review. Expert commentary: Improvements in MIC determination and therapeutic drug monitoring are needed to fully implement individualized dosing that optimizes antimicrobial pharmacodynamics.Additional data will become available for these agents in regards to effectiveness for severe MRSA infections and pharmacokinetic data for special patient populations.

Original languageEnglish
Pages (from-to)493-508
Number of pages16
JournalExpert Review of Clinical Pharmacology
Issue number5
StatePublished - 4 May 2017


  • antimicrobial
  • Dose optimization
  • MRSA
  • pharmacodynamics
  • pharmacokinetics


Dive into the research topics of 'Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)'. Together they form a unique fingerprint.

Cite this